

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM748366

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Termination and Release of Security Interest in Trademarks at Reel/Frame: 6798/0704		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
BIOPHARMA CREDIT PLC		08/12/2022	Public Limited Company: ENGLAND AND WALES
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	EPIZYME, INC.		
<b>Street Address:</b>	400 Technology Square		
<b>City:</b>	Cambridge		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	02139		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 5</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	87554273	TAZVERIK	
<b>Serial Number:</b>	87554277	TAZVYNDA	
<b>Registration Number:</b>	4045133	EPIZYME	
<b>Serial Number:</b>	88452418	EPIZYME	
<b>Registration Number:</b>	4049072	EPIZYME	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6175265000		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	720-274-3163		
<b>Email:</b>	huelinh.tran@wilmerhale.com		
<b>Correspondent Name:</b>	Benjamin S. Fernandez, Esquire		
<b>Address Line 1:</b>	Wilmer Cutler Pickering Hale and DorrLLP		
<b>Address Line 2:</b>	60 State Street		
<b>Address Line 4:</b>	Boston, MASSACHUSETTS 02109		
<b>NAME OF SUBMITTER:</b>	Benjamin S. Fernandez		
<b>SIGNATURE:</b>	/s/ Benjamin S. Fernandez		
<b>DATE SIGNED:</b>	08/13/2022		

OP \$140.00 87554273

**Total Attachments: 6**

source=termination of trademark security interest from biopharm credit to epizyme#page1.tif

source=termination of trademark security interest from biopharm credit to epizyme#page2.tif

source=termination of trademark security interest from biopharm credit to epizyme#page3.tif

source=termination of trademark security interest from biopharm credit to epizyme#page4.tif

source=termination of trademark security interest from biopharm credit to epizyme#page5.tif

source=termination of trademark security interest from biopharm credit to epizyme#page6.tif

## TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Termination and Release") dated as of August 12, 2022, is made by BIOPHARMA CREDIT PLC, as collateral agent for the Secured Parties (in such capacity, the "Collateral Agent"), in favor of EPIZYME, INC. (the "Grantor").

### RECITALS:

WHEREAS, the Grantor is a party to that certain Guaranty and Security Agreement, dated as of November 18, 2019 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Guaranty and Security Agreement"; terms used in this Termination and Release and not otherwise defined herein have the meanings set forth in the Guaranty and Security Agreement), by and among the Grantor, the other grantors party thereto, and the Collateral Agent pursuant to which each Grantor granted a security interest to the Collateral Agent in the Trademark Collateral (as defined below), including, but not limited to, those Trademarks listed on Schedule A hereto;

WHEREAS, the Grantor entered into that certain Trademark Security Agreement, dated as of November 18, 2019 (the "Trademark Security Agreement"), granting the Collateral Agent security interests in and liens on certain trademarks described therein (the "Trademark Collateral");

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office ("USPTO") on November 19, 2019 at Reel/Frame 006798/0704;

WHEREAS, the Grantor has requested that the Collateral Agent enter into this Termination and Release in order to effectuate, evidence and record the release and reassignment to the Grantor of any and all right, title and interest the Collateral Agent may have in the Trademark Collateral pursuant to the Trademark Security Agreement;

WHEREAS, the Collateral Agent desires to terminate and release its security interest in the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees:

SECTION 1. Release of Security Interest. The Collateral Agent hereby releases, terminates and discharges all liens and security interests the Collateral Agent has in, to and under the Trademark Collateral under the Trademark Security Agreement.

SECTION 2. Filing the Release. The Collateral Agent authorizes and requests that this Termination and Release be filed and recorded at the USPTO at the Grantor's sole cost and expense.

SECTION 3. Counterparts; Electronic Transmission. This Termination and Release may be executed and delivered by facsimile or other means of electronic transmission and such transmission shall constitute an original for all purposes.

SECTION 4. Governing Law. THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.


[Signature page follows this page.]

IN WITNESS WHEREOF, the undersigned has executed this Termination and Release by its duly authorized officer as of the date first above written.

BIOPHARMA CREDIT PLC,  
as Collateral Agent.

By: Pharmakon Advisors, LP,  
its Investment Manager

By: Pharmakon Management I, LLC,  
its General Partner

By   
Name: Pedro Gonzalez de Cosio  
Title: Managing Member


Schedule A  
Trademark Collateral

Trademarks, Trademark Applications (including any service marks, collective marks and certification marks) and Trademark Licenses

TRADEMARKS

Trademark	Status	Country	App. No.	Filing Date	Reg. No.	Reg. Date	Owner
TAZVERIK	Published	Argentina	3.790.064	01-Apr-2019			Epizyme, Inc.
TAZVERIK	Pending Designation	Australia	1368636	07-Aug-2017			Epizyme, Inc.
TAZVERIK	Registered	Brazil	913405442	18-Sep-2017	913405442	11-Dec-2018	Epizyme, Inc.
TAZVERIK	Allowed	Canada	1853269	18-Aug-2017			Epizyme, Inc.
TAZVERIK	Registered Designation	China (People's Republic)	1368636	07-Aug-2017	1368636	07-Aug-2017	Epizyme, Inc.
TAZVERIK	Registered Designation	European Union (Community)	1368636	07-Aug-2017	1368636	07-Aug-2017	Epizyme, Inc.
TAZVERIK	Registered Designation	India	1368636	07-Aug-2017	1368636	07-Aug-2017	Epizyme, Inc.
TAZVERIK	Registered	Int'l Registration - Madrid Protocol Only	A0068996	07-Aug-2017	1368636	07-Aug-2017	Epizyme, Inc.
TAZVERIK	Registered Designation	Japan	1368636	07-Aug-2017	1368636	07-Aug-2017	Epizyme, Inc.
TAZVERIK	Pending Designation	Korea, Republic of	1368636	07-Aug-2017			Epizyme, Inc.
TAZVERIK	Pending Designation	Mexico	1368636	07-Aug-2017			Epizyme, Inc.
TAZVERIK	Registered Designation	Russian Federation	1368636	07-Aug-2017	1368636	07-Aug-2017	Epizyme, Inc.

TAZVERIK	Pending Designation	Switzerland	1368636	07-Aug-2017			Epizyme, Inc.
TAZVERIK	Allowed	United States of America	87/554273	03-Aug-2017			Epizyme, Inc.
TAZVYND A	Pending Designation	Australia	1368635	07-Aug-2017			Epizyme, Inc.
TAZVYND A	Registered	Brazil	913405531	18-Sep-2017	913405531	11-Dec-2018	Epizyme, Inc.
TAZVYND A	Allowed	Canada	1853270	18-Aug-2017			Epizyme, Inc.
TAZVYND A	Registered Designation	China (People's Republic)	1368635	07-Aug-2017	1368635	07-Aug-2017	Epizyme, Inc.
TAZVYND A	Registered Designation	European Union (Community)	1368635	07-Aug-2017	1368635	07-Aug-2017	Epizyme, Inc.
TAZVYND A	Registered Designation	India	1368635	07-Aug-2017	1368635	07-Aug-2017	Epizyme, Inc.
TAZVYND A	Registered	Int'l Registration - Madrid Protocol Only	A0068997	07-Aug-2017	1368635	07-Aug-2017	Epizyme, Inc.
TAZVYND A	Registered Designation	Japan	1368635	07-Aug-2017	1368635	07-Aug-2017	Epizyme, Inc.
TAZVYND A	Pending Designation	Korea, Republic of	1368635	07-Aug-2017			Epizyme, Inc.
TAZVYND A	Pending Designation	Mexico	1368635	07-Aug-2017			Epizyme, Inc.
TAZVYND A	Registered Designation	Russian Federation	1368635	07-Aug-2017	1368635	07-Aug-2017	Epizyme, Inc.
TAZVYND A	Pending Designation	Switzerland	1368635	07-Aug-2017			Epizyme, Inc.
TAZVYND A	Allowed	United States of America	87/554277	03-Aug-2017			Epizyme, Inc.
EPIZYME	Registered Designation	Australia	1075801	07-Apr-2011	1426894	14-Nov-2011	Epizyme, Inc.
EPIZYME	Registered Designation	European Union (Community)	1075801	07-Apr-2011	1075801	07-Apr-2011	Epizyme, Inc.
EPIZYME	Registered	India	2132977	20-Apr-2011	2132977	07-Nov-2013	Epizyme, Inc.
EPIZYME	Registered	Int'l Registration - Madrid Protocol Only	A0024085	07-Apr-2011	1075801	07-Apr-2011	Epizyme, Inc.

EPIZYME	Registered Designation	Korea, Republic of	1075801	07-Apr-2011	1075801	07-Apr-2011	Epizyme, Inc.
EPIZYME	Registered	United States of America	85/280475	29-Mar-2011	4045133	25-Oct-2011	Epizyme, Inc.
EPIZYME	Pending	United States of America	88/452418	30-May-2019			Epizyme, Inc.
	Registered	United States of America	85/288886	07-Apr-2011	4049072	01-Nov-2011	Epizyme, Inc.
タズベリンカ	Pending	Japan	2019-087322	21-Jun-2019			Epizyme, Inc.
タゼベリンカ	Pending	Japan	2019-087323	21-Jun-2019			Epizyme, Inc.
タズベリンカ	Pending	Japan	2019-087325	21-Jun-2019			Epizyme, Inc.
タゼベリンカ	Pending	Japan	2019-087324	21-Jun-2019			Epizyme, Inc.

TRADEMARK LICENSES

1. Companion Diagnostics Agreement dated as of December 18, 2012 between the Borrower and Eisai Co., Ltd. on the one side and Roche Molecular Systems, Inc. on the other side, as amended.